Abstracts tagged "Lupus"

Abstract Number: 1675 • 2018 ACR/ARHP Annual Meeting
Lupus Impact Tracker Responds to Changes in Low Disease Activity and Remission Outcomes in a Large Spanish Lupus Registry Cohort
Meenakshi Jolly¹, Hervé Devilliers², Iñigo Rúa-Figueroa³, Desiree R Azizoddin⁴, Raúl Menor Almagro⁵, Francisco Javier López Longo⁶, Juan Gabriel Ovalles-Bonilla⁷, Alejandro Olivé-Marques⁸, Paula Rubio-Muñoz⁸, María Galindo-Izquierdo⁹, Antonio Fernandez-Nebro¹⁰, Jaime Calvo-Alen¹¹, Txaro García de Vicuña-Pinedo¹², Eva G Tomero-Muriel¹³, Esther Uriarte Isacelaya¹⁴, Angela Pecondon-Español¹⁵, Mercedes Freire-González¹⁶, Ricardo Blanco¹⁷, Marian Gantes Mora¹⁸, Monica Ibanez Barcelo¹⁹, Carlos Alberto Montilla-Morales²⁰, José José C Rosas-Gómez de Salazar²¹, Jesús García-Villanueva²², Paloma Vela-Casasempere²³, María E Ruiz-Lucea²⁴, Francisco J Toyos-Sáenz-de-Miera²⁵, José Hernández Beiraín²⁶, Elvira Diez Alvarez²⁷, Gema Bonilla-Hernán²⁸, Javier Narváez-García²⁹, José Andréu-Sánchez³⁰, Mireia Moreno-Martínez-Losa³¹, Ana Sánchez Atrio³², Maria Loreto Horcada³³, Tatiana Cobo-Ibáñez³⁴, Carlos Marras Fernandez-Cid³⁵, Tomas Ramón Vazquez Rodriguez³⁶, Eva Salgado-Pérez³⁷, Vicente Torrente³⁸, Juan Alegre-Sancho³⁹, Coral Mouriño-Rodriguez⁴⁰, Joel A. Block¹ and JM Pego-Reigosa⁴¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²de médecine Interne, Hôpital Universitaire Dijon, Dijon, France, ³Rheumatology Division, Hospital Doctor Negrin, Las Palmas GC, Spain, ⁴Department of Anesthesiology, Stanford University School of Medicine, Palo Alto, CA, ⁵Rheumatology, Hospital de Jerez de la Frontera, Jerez, Spain, ⁶Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁷Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain, ⁸Rheumatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁹Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain, ¹⁰UGC de Reumatología, Instituto de Investigación Biomédica de Málaga (IBIMA) Hospital Regional Universitario de Málaga Departamento de Medicina y Dermatología, Universidad de Málaga, MÁLAGA, Spain, ¹¹Rheumatology, Txagorritxu Hospital, Araba, Vitoria, Vitoria, Spain, ¹²Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ¹³Rheumatology, Hospital de La Princesa. Madrid. Spain, Madrid, Spain, ¹⁴Rheumatology, Hospital Universitario de Donosti, San Sebastian, Spain, ¹⁵Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ¹⁶Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo HospitalarioUniversitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain, ¹⁷Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ¹⁸Rheumatology, Hospital Universitario de Canarias, La Laguna; Tenerife, Spain, ¹⁹H. Son Llatzer, Palma de Mallorca, Spain, ²⁰Hospital Clínico Universitario de Salamanca. Spain, Salamanca, Spain, ²¹Rheumatology, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ²²HOSPITAL RAMÓN Y CAJAL, Madrid, Spain, ²³Dpt. Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ²⁴Rheumatology, Hospital de Basurto, Bilbao, Spain, ²⁵Rheumatology, Hospital Universitario Virgen de la Macarena, Sevilla, Spain, ²⁶Rheumatology, Hospital Insular de Gran Canaria, Las palmas Gran Canarias, Spain, ²⁷Complejo Asistencial Universitario de León, León, Spain, ²⁸Rheumatology Department, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain, ²⁹Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, ³⁰HOSPITAL PUERTA DE HIERRO, Madrid, Spain, ³¹HOSPITAL PARC TAULÍ, Barcelona, Spain, ³²University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology Department, Alcalá de Henares, Madrid, Spain, ³³Rheumatology, Hospital de Navarra, Pamplona, Spain, ³⁴Hospital Universitario Reina Sofía, Universidad Europea de Madrid, Madrid, Spain, ³⁵Rheumatology, Hospital Virgen de la Arrixaca, Murcia, Spain, ³⁶Rheumatology, Hospital Universitario Lucus Augusti, Lugo, Spain, ³⁷COMPLEJO HOSPITALARIO DE OURENSE, Ourense, Spain, ³⁸Hospital Sant Joan de Déu, Esplugues de Llobregat, Spain, ³⁹HOSPITAL DR. PESET, València, Spain, ⁴⁰Rheumatology, Rheumatology Section, Complexo Hospitalario Universitario de Vigo, Pontevedra, Spain, Vigo, Spain, ⁴¹Complexo Hospitalario Universitario de Vigo, Vigo, Spain
Background/Purpose: Remission & Low Disease activity state (LDAS) are the two new health outcome measures developed with “treat to target” strategy in mind for Systemic…
Abstract Number: 2094 • 2018 ACR/ARHP Annual Meeting
Examining T Cell Exhaustion in Murine Systemic Lupus Erythematosus
Jeremy Tilstra¹, Lyndsay Avery², Ashley Menk², Rachael Gordon², Shuchi Smita³, Lawrence Kane³, Maria Chikina², Greg Delgoffe³ and Mark Shlomchik⁴, ¹Rheumatology, Univ of Pittsburgh Medical Center, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³Department of Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: While T cells are important for the pathogenesis of systemic lupus erythematosus (SLE) and lupus nephritis, little is known about how T cells function…
Abstract Number: 2679 • 2018 ACR/ARHP Annual Meeting
Glucocorticoids Withdrawal in Systemic Lupus Erythematosus: Are Remission and Low Disease Activity Reliable Starting Points for Stopping Therapy? a Real-Life Experience
Viola Signorini, Chiara Tani, Elena Elefante, Chiara Stagnaro, Linda Carli and Marta Mosca, Rheumatology Unit, University of Pisa, Pisa, Italy
Background/Purpose: Glucocorticoids (GC) are a cornerstone of the treatment of Systemic Lupus Erythematosus (SLE); however, a significant organ damage is associated with long-term GC use…
Abstract Number: 291 • 2018 ACR/ARHP Annual Meeting
Factors Associated with High-Dose Corticosteroid Use in SLE Patients Post Initiation of SLE Therapy
Krista Schroeder¹, Steve Gelwicks¹, Jim Paik² and Robert W. Hoffman¹, ¹Eli Lilly and Company, Indianapolis, IN, ²HEOR, Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Systemic lupus erythematosus (SLE) therapies include non-steroidal anti-inflammatory drugs, antimalarials, systemic immunosuppressants, and biologics with corticosteroids as necessary. The majority of these current therapies…
Abstract Number: 736 • 2018 ACR/ARHP Annual Meeting
Herpes Zoster and Disseminated Zoster in Systemic Lupus Erythematosus and Lupus Nephritis: Incidence Rates in Real-World Claims Data
Katherine Belendiuk¹, Yingjie Ding², Devika Chawla¹ and Matthew Cascino¹, ¹Genentech, Inc., South San Francisco, CA, ²Genesis Research, Hoboken, NJ
Background/Purpose: Disseminated zoster is a highly morbid complication of varicella zoster reactivation (herpes zoster) that is typically associated with immunosuppression. Systemic lupus erythematosus (SLE) and…
Abstract Number: 1680 • 2018 ACR/ARHP Annual Meeting
Serum Calprotectin in Systemic Lupus Erythematosus: Is It a Good Activity Biomarker?
Jordi Camins Fàbregas¹, Melania Martinez-Morillo¹, Laia Gifre¹, Susana Holgado¹, Lourdes Mateo², Maria Aparicio¹, Anne Riveros², Ivette Casafont-Solé¹, Yaiza Garcia¹, Agueda Prior³, Aina Teniente-Serra⁴, Eva Martínez-Cáceres⁴ and Alejandro Olivé-Marqués², ¹Rheumatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ³Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ⁴Immunology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
Background/Purpose: Clinical manifestations of systemic lupus erythematosus (SLE) and infections sometimes are difficult to distinguish. In clinical practice low complement and anti(ds)DNA levels are used…
Abstract Number: 2099 • 2018 ACR/ARHP Annual Meeting
Bruton’s Tyrosine Kinase (BTK) Inhibition Modulates Multiple Cell Types Instrumental in the Pathogenesis of Lupus Nephritis
Samantha Chalmers¹, Sayra Garcia¹, Elliott Klein², Jay S. Fine², Gerald Nabozny³, Meera Ramanujam² and Chaim Putterman⁴, ¹Albert Einstein College of Medicine, Bronx, NY, ²Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ³[email protected], Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ⁴Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY
Background/Purpose: Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus (SLE) that adds substantial morbidity and mortality. Passive transfer of pre-formed nephritogenic antibodies…
Abstract Number: 2684 • 2018 ACR/ARHP Annual Meeting
Type I IFN, TLR7, MHC Class I, B Cell and OX40 Pathways Suppressed By Anifrolumab (anti-type I IFN receptor) in Moderate to Severe SLE Patients
Katie Streicher¹, Jixin Wang¹, Philip Z. Brohawn², Brandon W. Higgs², Raj Tummala³ and Koustubh Ranade⁴, ¹Translational Medicine, MedImmune, Gaithersburg, MD, ²MedImmune LLC, Gaithersburg, MD, ³MedImmune, Gaithersburg, MD, ⁴Translational Medicine, MedImmune LLC, Gaithersburg, MD
Background/Purpose: Type I interferon has been identified as one of the central mediators in the pathogenesis of SLE, such that patients are characterized by activation…
Abstract Number: 395 • 2018 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus (SLE) with Inflammatory Myositis
Nicole Bitencourt, Elizabeth (Blair) Solow and Bonnie L. Bermas, Division of Rheumatic Diseases, UT Southwestern Medical Center, Dallas, TX
Background/Purpose: The goal of this study was to identify specific clinical features of patients with SLE who have inflammatory myositis. Methods: A retrospective chart review…
Abstract Number: 743 • 2018 ACR/ARHP Annual Meeting
Outcome of Stroke in Patients with Systemic Lupus Erythematosus: A Nested Case-Control Study
Chi Chiu Mok, Lap Kiu Tsoi and Yat Pang Fu, Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong
Background/Purpose: To evaluate the outcome of stroke in patients with systemic lupus erythematosus (SLE) in comparison with non-SLE patients. Methods: Patients who fulfilled ≥4 SLICC/ACR…
Abstract Number: 1689 • 2018 ACR/ARHP Annual Meeting
Explaining the Discrepancy between Physician and Patient-Reported Measures of Disease Activity in Systemic Lupus Erythematosus
Nathaniel J. Harris¹, Amanda M. Eudy² and Megan E. B. Clowse², ¹Department of Medicine, Duke University, Durham, NC, ²Department of Medicine, Division of Rheumatology and Immunology, Duke University, Durham, NC
Explaining the Discrepancy between Physician and Patient-Reported Measures of Disease Activity in Systemic Lupus Erythematosus Background/Purpose: Patient-reported measures of disease activity provide useful adjuncts to…
Abstract Number: 2100 • 2018 ACR/ARHP Annual Meeting
Topical Endocannabinoid Administration Protects MRL-Lpr/Lpr Mice from Cutaneous Lupus Erythematosus
Samantha Chalmers¹, Sayra Garcia¹, Andrew Draganski¹, Jessica Doerner², Adam Friedman³, Joel Friedman¹ and Chaim Putterman⁴, ¹Albert Einstein College of Medicine, Bronx, NY, ²University of Pennsylvania, Philadelphia, PA, ³Dermatology, GW School of Medicine and Health Sciences, Washington, DC, ⁴Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY
Background/Purpose: Cutaneous lupus erythematosus (CLE) affects ~75% of SLE patients and has a profound impact on quality of life. While the morbidity from CLE is…
Abstract Number: 2796 • 2018 ACR/ARHP Annual Meeting
Sex-Based Differences Control ABC Function in Swef-Deficient Mice
Michela Manni¹, Danny Flores-Castro², Chao Ye², Edd Ricker¹, Sanjay Gupta³, Yurii Chinenov⁴, Tania Pannellini² and Alessandra B. Pernis⁵, ¹Autoimmunity and Inflammation Program, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Autoimmunity & Inflammation Research Program, Hospital for Special Surgery, New York, NY, ⁴Arthritis & Tissue Degeneration Program, Hospital for Special Surgery, New York, NY, ⁵David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY
Background/Purpose: Age-associated B cells (ABCs) are a novel B cell subset, which expands with age in non-autoimmune mice but accumulates prematurely in autoimmune-prone strains. ABCs…
Abstract Number: 459 • 2018 ACR/ARHP Annual Meeting
Readmission Rate within 30 Days of Hospitalization Due to New Onset Lupus Nephritis and Associated Risk Factors: The Importance of Intravenous Pulse Methylprednisolone Therapy
Angel Alberto Herrera Guerra¹, Sampath Prahalad¹, Kelly A. Rouster-Stevens¹, Rouba Garro², Leah Bryan³ and Yin Hong⁴, ¹Pediatric Rheumatology, Emory University School of Medicine, Atlanta, GA, ²Pediatric Nephrology, Emory University School of Medicine, Atlanta, GA, ³Pediatrics, Emory University School of Medicine, Atlanta, GA, ⁴Pathology, Children's Health Care of Atlanta, Atlanta, GA
Background/Purpose: There is a paucity of data regarding the early hospital readmission rates in newly diagnosed childhood lupus nephritis (cLN). We conducted a retrospective study…
Abstract Number: 748 • 2018 ACR/ARHP Annual Meeting
Long-Term Survival of Renal Transplantation Due to Lupus Nephritis. Comparative Study with Non-Autoimmune Transplantation. Study from a Single Center
Lara Sánchez-Bilbao¹, Belén Atienza-Mateo¹, José Luis Martín-Varillas¹, Marina de Cos-Gómez², Íñigo González-Mazón¹, Diana Prieto Peña³, Monica Calderón Goercke³, Juan Carlos Ruiz San Millán², Emilio Rodrigo Calabia², Miguel Angel González-Gay¹ and Ricardo Blanco¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Nephrology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain
Background/Purpose: Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus, affecting up to 40% of patients. Unfortunately, about 20% of LN develop end…

« Previous Page
1
…
8
9
10
11
12
…
31
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].